OrganiGram Holdings Stock (NASDAQ:OGI), Trade Ideas

OrganiGram Holdings

OrganiGram Holdings Inc is engaged in producing indoor-grown cannabis for patients and adult recreational consumers in Canada. The company has also developed a portfolio of adult-use recreational cannabis brands including Edison, Big Bag o' Buds, SHRED, Monjour, Holy Mountain, and Trailblazer. Tremblant Cannabis, and artisanal craft brand, Laurentian are recent additions to Organigram's existing brand portfolio.

Cannabis,Tax,Sign,With,Message,Green,Cannabis,And,Dollar,Signs

Cannabis

News

TLRY

No Cannabis Tax Relief In Canada, Tilray CEO Says This &#39;Hinders Our Ability To Compete With The Illicit Market&#39;

cannabis contract signing BZCCC (Iryna Rahalskaya on Shutterstock)(36)

Exclusives

California-based I Love Growing Marijuana (ILGM), announced on Tuesday an exclusive new partnership with cannabis genetics and breeding company, Phylos Bioscience, that brings 15 new F1 hybrid strains to home growers across legal markets nationwide. ILGM is launching half the collection of strains that are &#34;crafted for potency, flavor, and diversity&#34; on its website just in time for marijuana culture&#39;s high holiday on 4/20. In doing so, the company is leveraging Phylos Bioscience&#39;s cutting-edge technology and extensive genetic library, which Benzinga has learned exclusively. Ernst Rustenhoven, CEO of ILGM, commented on the new partnership. &#34;ILGM caters to a customer base of novice and veteran home growers on the hunt for increasingly unique strains of superior genetics, and we have been seeking an innovative partner to help elevate and diversify our product offerings,&#34; Rustenhoven said. &#34;In forging a relationship with Phylos, we are taking our seed catalog to the next level with a highly curated selection of sought-after F1 hybrid strains.&#34;

EXCLUSIVE: Fifteen New F1 Hybrid Cannabis Strains To Hit Shelves In US For 4/20 Under New Partnership

AI Generated Image 

Analyst Color

Equities

Penny Stocks

Retail Sales

Small Cap

Management

Market-Moving Exclusives

Markets

Analyst Ratings

Trading Ideas

AVTBF

CRON

DBCCF

GTBIF

SNDL

TCNNF

TSXV:LOVE

The Canadian cannabis sector is witnessing a notable upswing, driven by recent developments including Tilray&#39;s (NASDAQ: TLRY) earnings report, Organigram&#39;s investor day (NASDAQ: OGI) and pivotal movements by Canopy Growth (NASDAQ: 

NASDAQ-Listed Marijuana Stocks, Tilray, Canopy, Aurora Rally: What&#39;s Behind The Surge?

OrganiGram Holdings Inc

ALPS O'Shares Global Internet Giants ETF

<p><strong>MacroGenics Inc</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) released interim data from the TAMARACK Phase 2 study of&nbsp;vobramitamab&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38762671" rel="noreferrer noopener">duocarmazine (vobra duo)</a>.</p>
<p>TAMARACK is being conducted in previously treated patients with metastatic castration-resistant prostate cancer (mCRPC).</p>
<p>MacroGenics reported five deaths (fatal outcome) during the trial. It also reported over 50% rate of grade 3, or worse, adverse events in both dose cohorts (2 mg/kg and 2.7 mg/kg every four weeks).</p>
<ul>
<li>B Riley maintains the Buy rating on MacroGenics <a href="https://www.benzinga.com/quote/MGNX/analyst-ratings" target="_blank" rel="noreferrer noopener">with a price target of $25</a>. </li>
<li>BMO Capital Markets downgraded MacroGenics from Outperform to Market Perform with a price target of $8 from $24 on lower conviction on the prostate cancer program.</li>
<li>JMP writes while maintaining the Outperform rating.</li>
</ul>
<p><strong>B Riley</strong>&nbsp;notes that an unexpected increase in treatment interruptions and discontinuations from week 12 to week 24 could imply a lower likelihood of success in a relatively crowded mCRPC landscape.</p>
<p>The firm notes that >Grade 1 Palmar-plantar erythrodysaesthesia (PPE) cases at wk-24 were just 4.4%/10% in the 2/2.7 mg/kg arms vs. 31% reported in the 3 mg/kg arm, representing a significant improvement in what was the most concerning side-effect.</p>
<p>Strong clinical activity was observed even in the 2 mg/ kg arm.</p>
<p><strong>BMO Capital Markets</strong>&#8216; analyst previously discussed the competitive landscape in metastatic castration-resistant prostate cancer (mCRPC) and the standards anticipated MacroGenics needed to meet in the recently revealed TAMARACK results. However, the effectiveness and safety updates from the study failed to meet expectations.</p>
<p><strong>JMP Securities&nbsp;</strong>writes, &#8220;We were surprised by five newly reported deaths in the data, which will likely lead to volatility.&#8221;</p>
<p>Based on&nbsp;<strong>Novartis AG&#8217;s</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) PSMAfore and<strong>&nbsp;Exelixis Inc&#8217;s&nbsp;</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) CONTACT-02, the analyst points out that the death rate in the mCRPC setting is ~2-12%, and the recorded deaths in TAMARACK (2.8% of patients) fall within this range.</p>
<p>JMP says ORR is the highlight of the update. There is a large discrepancy between confirmed and unconfirmed numbers, but 18-25% (confirmed) and 24-44% (total) compare well.&nbsp;</p>
<p>Cabo+Atezo (CONTACT-02 showed a 14% ORR), Pluvicto has a 51% ORR, and emerging bispecifics have an ORR of 41-56%.</p>
<p>&#8220;Overall, given several new compounds vying for a place in mCRPC, we need to wait for the 2H24 data to form a full picture of the opportunity,&#8221; JMP writes.</p>
<p><strong>Price Action:</strong>&nbsp;MGNX shares&nbsp;are&nbsp;down 77.7% at $3.27&nbsp;at last check&nbsp;Friday.</p>
<p><em>Now Read: <a href="https://www.benzinga.com/general/entertainment/24/05/38768543/planet-fitness-raises-new-member-price-after-tough-controversy-filled-q1">Planet Fitness Raises New Member Price After Tough, Controversy-Filled Q1</a></em></p>


Biotech

Downgrades

Health Care

Price Target

Movers

General

EXEL

MGNX

MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'

<p>Barclays  analyst Adrienne Yih   maintains Hanesbrands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) with a Equal-Weight and raises the price target from $4 to $5.</p>


Barclays Maintains Equal-Weight on Hanesbrands, Raises Price Target to $5

<p>Barclays  analyst Andrew Lazar   maintains Hain Celestial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>) with a Equal-Weight and lowers the price target from $8 to $7.</p>


HAIN

Barclays Maintains Equal-Weight on Hain Celestial Group, Lowers Price Target to $7

<p>Deep-pocketed investors have adopted a bearish approach towards NextEra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NEE usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for NextEra Energy. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 36% leaning bullish and 45% bearish. Among these notable options, 3 are puts, totaling $134,889, and 8 are calls, amounting to $2,483,026.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $80.0 for NextEra Energy during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for NextEra Energy's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of NextEra Energy's whale activity within a strike price range from $50.0 to $80.0 in the last 30 days. </p>
<h3>NextEra Energy Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715367967_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NEE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.35</td>
<td>$6.1</td>
<td>$6.3</td>
<td>$80.00</td>
<td>$2.2M</td>
<td>7.0K</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>NEE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$4.85</td>
<td>$4.8</td>
<td>$4.85</td>
<td>$75.00</td>
<td>$81.0K</td>
<td>3.1K</td>
<td style="text-align: right;">185</td>
</tr>
<tr>
<td>NEE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$3.65</td>
<td>$3.6</td>
<td>$3.61</td>
<td>$72.50</td>
<td>$71.6K</td>
<td>1.8K</td>
<td style="text-align: right;">349</td>
</tr>
<tr>
<td>NEE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$5.05</td>
<td>$4.95</td>
<td>$5.05</td>
<td>$70.00</td>
<td>$45.9K</td>
<td>9.2K</td>
<td style="text-align: right;">193</td>
</tr>
<tr>
<td>NEE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$9.6</td>
<td>$9.1</td>
<td>$9.5</td>
<td>$65.00</td>
<td>$37.8K</td>
<td>15.8K</td>
<td style="text-align: right;">27</td>
</tr>
</tbody>
</table>
</p>
<h3>About NextEra Energy</h3>
<p>NextEra Energy's regulated utility, Florida Power &amp; Light, is the largest rate-regulated utility in Florida. The utility distributes power to nearly 6 million customer accounts in Florida and owns 34 gigawatts of generation. FP&amp;L contributes roughly 70% of NextEra's consolidated operating earnings. NextEra Energy Resources, the renewable energy segment, generates and sells power throughout the United States and Canada with more than 30 GW of generation capacity, including natural gas, nuclear, wind, and solar.</p>
<p>Having examined the options trading patterns of NextEra Energy, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of NextEra Energy</h3>
<ul>
<li>With a trading volume of 8,188,756, the price of NEE is down by -1.09%, reaching $73.77.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 74 days from now.</li>
</ul>
<h3>What Analysts Are Saying About NextEra Energy</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $71.6.</p>
<ul>
<li>An analyst from BMO Capital has decided to maintain their Outperform rating on NextEra Energy, which currently sits at a price target of $68. </li>
<li>Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for NextEra Energy, targeting a price of $72. </li>
<li>An analyst from B of A Securities has decided to maintain their Neutral rating on NextEra Energy, which currently sits at a price target of $67. </li>
<li>Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on NextEra Energy with a target price of $78. </li>
<li>Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Outperform rating for NextEra Energy, targeting a price of $73. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for NextEra Energy, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

This Is What Whales Are Betting On NextEra Energy

<p>Deep-pocketed investors have adopted a bearish approach towards Globe Life (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GL#NYSE">GL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GL usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Globe Life. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 40% leaning bullish and 60% bearish. Among these notable options, 4 are puts, totaling $125,662, and 6 are calls, amounting to $312,205.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $85.0 and $115.0 for Globe Life, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Globe Life's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Globe Life's substantial trades, within a strike price spectrum from $85.0 to $115.0 over the preceding 30 days.</p>
<h3>Globe Life Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715367962_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>GL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.9</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$105.00</td>
<td>$81.0K</td>
<td>236</td>
<td style="text-align: right;">191</td>
</tr>
<tr>
<td>GL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$1.15</td>
<td>$1.1</td>
<td>$1.15</td>
<td>$90.00</td>
<td>$73.5K</td>
<td>3.0K</td>
<td style="text-align: right;">113</td>
</tr>
<tr>
<td>GL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.0</td>
<td>$2.4</td>
<td>$3.0</td>
<td>$115.00</td>
<td>$60.0K</td>
<td>10</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>GL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/28/24</td>
<td>$4.0</td>
<td>$3.6</td>
<td>$4.0</td>
<td>$85.00</td>
<td>$40.0K</td>
<td>0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>GL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/24/24</td>
<td>$0.65</td>
<td>$0.65</td>
<td>$0.65</td>
<td>$95.00</td>
<td>$39.1K</td>
<td>156</td>
<td style="text-align: right;">531</td>
</tr>
</tbody>
</table>
</p>
<h3>About Globe Life</h3>
<p>Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into four reportable segments: life insurance, supplemental health insurance, annuities, and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.</p>
<p>Having examined the options trading patterns of Globe Life, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Globe Life</h3>
<ul>
<li>Trading volume stands at 1,159,003, with GL's price up by 0.73%, positioned at $87.51.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 75 days.</li>
</ul>
<h3>What Analysts Are Saying About Globe Life</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $104.4.</p>
<ul>
<li>An analyst from Keefe, Bruyette &amp; Woods upgraded its action to Outperform with a price target of $110. </li>
<li>Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Globe Life, targeting a price of $132. </li>
<li>Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Globe Life, targeting a price of $125. </li>
<li>An analyst from Truist Securities has decided to maintain their Hold rating on Globe Life, which currently sits at a price target of $80. </li>
<li>Maintaining their stance, an analyst from Evercore ISI Group continues to hold a In-Line rating for Globe Life, targeting a price of $75. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Globe Life, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Looking At Globe Life's Recent Unusual Options Activity

<p>Financial giants have made a conspicuous bullish move on Deere. Our analysis of options history for Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) revealed 8 unusual trades.</p>
<p>Delving into the details, we found 50% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $64,300, and 6 were calls, valued at $512,647.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $382.5 and $430.0 for Deere, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Deere's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Deere's significant trades, within a strike price range of $382.5 to $430.0, over the past month.</p>
<h3>Deere Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715367957_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$52.5</td>
<td>$49.4</td>
<td>$52.5</td>
<td>$410.00</td>
<td>$225.7K</td>
<td>46</td>
<td style="text-align: right;">44</td>
</tr>
<tr>
<td>DE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$26.3</td>
<td>$26.0</td>
<td>$26.0</td>
<td>$410.00</td>
<td>$130.0K</td>
<td>807</td>
<td style="text-align: right;">3</td>
</tr>
<tr>
<td>DE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$9.2</td>
<td>$8.75</td>
<td>$8.97</td>
<td>$410.00</td>
<td>$54.6K</td>
<td>702</td>
<td style="text-align: right;">215</td>
</tr>
<tr>
<td>DE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$20.1</td>
<td>$19.8</td>
<td>$20.02</td>
<td>$400.00</td>
<td>$42.0K</td>
<td>1.6K</td>
<td style="text-align: right;">58</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$1.94</td>
<td>$1.71</td>
<td>$1.8</td>
<td>$382.50</td>
<td>$37.8K</td>
<td>60</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Deere</h3>
<p>Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 2,000 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.</p>
<h3>Current Position of Deere</h3>
<ul>
<li>With a trading volume of 913,084, the price of DE is down by -0.11%, reaching $408.56.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 6 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Deere</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $425.0.</p>
<ul>
<li>Consistent in their evaluation, an analyst from JP Morgan keeps a Neutral rating on Deere with a target price of $425. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Deere, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Looking At Deere's Recent Unusual Options Activity

<p>Barclays  analyst Lauren Lieberman   maintains Edgewell Personal Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>) with a Equal-Weight and raises the price target from $37 to $40.</p>


Barclays Maintains Equal-Weight on Edgewell Personal Care, Raises Price Target to $40

Macro Economic Events

Economics

Federal Reserve

Treasury Sec. Yellen Says Growing Nonbank Mortgage Sector Presents Unique Risks, Requires Greater Oversight To Protect Financial Stability; U.S. Financial Stability Oversight Council Set To Recommend Congress Help Regulators Promote Safety, Soundness Of Nonbank Mortgage Sector

<p>Barclays  analyst Adam Seiden   maintains Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) with a Overweight and raises the price target from $35 to $43.</p>


BLBD

Barclays Maintains Overweight on Blue Bird, Raises Price Target to $43

<p><strong>Hedera's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/hbar/usd">HBAR</a>) price has decreased 3.16% over the past 24 hours to <strong>$0.11</strong>, continuing its downward trend over the past week of -5.0%, moving from $0.11 to its current price. </p>
<p>The chart below compares the price movement and volatility for Hedera over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715367826_0.png" alt="price_chart" /></p>
<p>The trading volume for the coin has tumbled 64.0% over the past week along with the circulating supply of the coin, which has fallen 0.19%. This brings the circulating supply to 35.74 billion, which makes up an estimated 71.48% of its max supply of 50.00 billion. According to our data, the current market cap ranking for HBAR is #30 at $3.80 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715367826_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$HBAR

Cryptocurrency Hedera Falls More Than 3% In 24 hours

<p><i>Board of Directors Removes Anthony Geisler from CEO Duties, Discloses Investigation, and Reaffirms Guidance</i></p>
<p>Xponential Fitness, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) ("Xponential" or the "Company"), today announced that the Company's Board of Directors has appointed Brenda Morris, an experienced C-Suite executive and member of Xponential's Board of Directors since 2019, as interim Chief Executive Officer, effective immediately. In connection with Ms. Morris' appointment as Interim CEO, Chelsea Grayson has been appointed Lead Independent Director of the Board. The Board has removed Anthony Geisler from his duties and suspended him indefinitely as CEO, also effective immediately.</p>
<p>The Company received notice on May 7, 2024 of an investigation by the United States Attorney's Office for the Central District of California ("USAO"). The Company previously disclosed an investigation by the Securities and Exchange Commission ("SEC"). The Company intends to continue cooperating with the SEC and intends to cooperate with the USAO. The Board has formed a Special Committee of Directors, comprising independent directors Ms. Grayson, Jair Clarke and Jeffrey Lawrence, to investigate these matters.</p>


Guidance

XPOF

Xponential Fitness Names Brenda Morris Interim CEO, Board Has Removed Anthony Geisler From His Duties And Suspended Him Indefinitely As CEO, Effective Immediately; Discloses Investigation And Reaffirms Guidance

<p>Barclays  analyst Ramsey El-Assal   maintains BigCommerce Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIGC#NASDAQ">BIGC</a>) with a Equal-Weight and raises the price target from $7 to $8.</p>


BIGC

Barclays Maintains Equal-Weight on BigCommerce Holdings, Raises Price Target to $8

<p><strong>Cosmos Hub's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/atom/usd">ATOM</a>) price has decreased 3.73% over the past 24 hours to <strong>$8.75</strong>, continuing its downward trend over the past week of -1.0%, moving from $8.8 to its current price. </p>
<p>The chart below compares the price movement and volatility for Cosmos Hub over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715367756_0.png" alt="price_chart" /></p>
<p>The trading volume for the coin has fallen 48.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has decreased 0.15%. This brings the circulating supply to 390.69 million. According to our data, the current market cap ranking for ATOM is #33 at $3.42 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715367756_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$ATOM

Cryptocurrency Cosmos Hub Decreases More Than 3% Within 24 hours

<p>Over the past 24 hours, <strong>Uniswap's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/uni/usd">UNI</a>) price has fallen 3.8% to <strong>$7.13</strong>. This continues its negative trend over the past week where it has experienced a 5.0% loss, moving from $7.43 to its current price. </p>
<p>The chart below compares the price movement and volatility for Uniswap over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715367746_0.png" alt="price_chart" /></p>
<p>The trading volume for the coin has decreased 16.0% over the past week, while the overall circulating supply of the coin has increased 0.29% to over 753.77 million. This puts its current circulating supply at an estimated 75.38% of its max supply, which is 1.00 billion. The current market cap ranking for UNI is #26 at $5.37 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715367746_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$UNI

Cryptocurrency Uniswap Down More Than 3% Within 24 hours

<p>HC Wainwright &amp; Co.  analyst Kevin Dede   maintains Marathon Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) with a Buy and lowers the price target from $35 to $27.</p>


MARA

HC Wainwright & Co. Maintains Buy on Marathon Digital Holdings, Lowers Price Target to $27

<p><strong>Wedbush</strong>&nbsp;analyst Daniel Ives reiterated the Outperform rating on&nbsp;<strong>SoundHound AI, Inc.&nbsp;</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>)&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/SOUN/analyst-ratings" rel="noreferrer noopener">with a price forecast of $9.</a></p>
<p>Following the first quarter results, the analyst notes that the company continues to see demand for its voice AI products picked up in the automotive and restaurant industries, signing various large brand deals that fuel growth while grabbing market share<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">&nbsp;in the conversational AI market.</a></p>
<p>The company&#8217;s subscription and bookings backlog increased to $682.0 million in the first quarter. Per Ives, this is due to&nbsp;strong&nbsp;product royalties and strength in the automotive segment as new and existing customers continue&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/05/38761378/whats-going-on-with-soundhound-ai-shares-friday" rel="noreferrer noopener">to show interest in its Chat AI platform</a>.</p>
<p>SoundHound fully closed its acquisition of SYNQ3 Restaurant Solutions, as the company is now the largest U.S. provider of voice AI for restaurants with over 10,000 signed locations and significantly more in the pipeline as the restaurant segment now represents ~30% of total revenue ahead of initial expectations of 20% for FY24.</p>
<p>The company noted strength across its partnership&nbsp;ecosystem&nbsp;highlighted by a new partnership with&nbsp;<strong>NVIDIA Corporation</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)&nbsp;where the company will deliver in-vehicle voice-enabled generative AI responses that don&#8217;t require connectivity.</p>
<p>SoundHound expects to see positive adjusted EBITDA in 2025 as the company is well-positioned to capitalize on the demand for AI chatbots with a strong focus on partnerships and more use cases&nbsp;being provided&nbsp;while expanding its voice-enabled ecosystem to accelerate growth and margins.</p>
<p>According to the analyst, this was a&nbsp;major&nbsp;step in the right direction for the SoundHound story as the company continues to build toward profitable growth with stable revenue pillars in Automotive/Restaurant and strong monetization capabilities to capture demand from enterprises across industries that seek ways to optimize efficiencies.&nbsp;</p>
<p>The analyst raised FY24 revenue outlook to $71.6 million from $70.2 million.</p>
<p><strong>Price Action: </strong>SOUN shares are trading higher by 7.3% to $5.10 at last check Friday. </p>
<p><em>Photo via Shutterstock</em></p>


Reiteration

NVDA

SOUN

SoundHound's AI Is Fueling Revenue Surge From Strong Demand In Automotive And Restaurant Sectors: Analyst

<p>United-Guardian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UG#NASDAQ">UG</a>) reported quarterly earnings of $0.20 per share. This is a 25 percent increase over earnings of $0.16 per share from the same period last year.  The company reported $3.25 million in sales this quarter. This is a 26.65 percent increase over sales of $2.57 million the same period last year.</p>


Earnings

United-Guardian Q1 EPS $0.20 Up From $0.16 YoY, Sales $3.25M Up From $2.57M YoY

<p>Throughout the last three months, 17 analysts have evaluated Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $230.71, a high estimate of $253.00, and a low estimate of $212.00. Surpassing the previous average price target of $225.27, the current average has increased by 2.41%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715367678_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of Travelers Companies among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Phillips</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$216.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Frank Lee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$252.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>Brian Meredith</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$230.00</td>
<td>$237.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$231.00</td>
<td>$241.00</td>
</tr>
<tr>
<td>Yaron Kinar</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$219.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Mark Dwelle</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$225.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>David Motemaden</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>Harry Fong</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Buy</td>
<td>$240.00</td>
<td>-</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$231.00</td>
<td>$241.00</td>
</tr>
<tr>
<td>Michael Ward</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$226.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Michael Phillips</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$230.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$212.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>David Motemaden</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$253.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$241.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$213.00</td>
<td>$194.00</td>
</tr>
<tr>
<td>Vikram Gandhi</td>
<td>HSBC</td>
<td>Raises</td>
<td>Hold</td>
<td>$240.00</td>
<td>$218.00</td>
</tr>
<tr>
<td>Paul Newsome</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$213.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Travelers Companies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Travelers Companies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Travelers Companies's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TRV/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Travelers Companies analyst ratings.</strong></a></p>
<h2>Get to Know Travelers Companies Better</h2>
<p>Travelers offers a broad product range and participates in both commercial and personal insurance lines. Its commercial operations offer a variety of coverage types for companies of any size but concentrate on serving midsize businesses. Its personal lines are roughly evenly split between auto and homeowners insurance. Travelers derives 6% of its premiums from foreign markets.</p>
<h3>Financial Insights: Travelers Companies</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Travelers Companies's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>15.7%</strong> as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>9.93%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Travelers Companies's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>4.47%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.88%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.32</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Travelers Companies Through 17 Analysts

<p>Over the past 24 hours, <strong>Lido Staked Ether's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">STETH</a>) price has fallen 3.6% to <strong>$2,905.79</strong>. This continues its negative trend over the past week where it has experienced a 6.0% loss, moving from $3,063.27 to its current price. </p>
<p>The chart below compares the price movement and volatility for Lido Staked Ether over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715367676_0.png" alt="price_chart" /></p>
<p>The trading volume for the coin has fallen 21.0% over the past week which is opposite, directionally, with the overall circulating supply of the coin, which has increased 0.16%. This brings the circulating supply to 9.36 million. According to our data, the current market cap ranking for STETH is #8 at $27.19 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715367676_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$STETH

Lido Staked Ether Down More Than 3% Within 24 hours

<p>In the latest quarter, 12 analysts provided ratings for argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for argenx, presenting an average target of $458.5, a high estimate of $521.00, and a low estimate of $402.00. This current average has increased by 5.43% from the previous average price target of $434.88. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715367657_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of argenx among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$468.00</td>
<td>$471.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$521.00</td>
<td>-</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$451.00</td>
<td>-</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$451.00</td>
<td>$451.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$408.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$471.00</td>
<td>-</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$440.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$402.00</td>
<td>$346.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$471.00</td>
<td>$462.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$490.00</td>
<td>$505.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$451.00</td>
<td>-</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$478.00</td>
<td>$472.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to argenx. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of argenx compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of argenx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of argenx's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ARGX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on argenx analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind argenx</h2>
<p>Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.</p>
<h3>Breaking Down argenx's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, argenx showcased positive performance, achieving a revenue growth rate of <strong>133.6%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> argenx's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-24.38%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> argenx's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-2.42%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> argenx's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-2.18%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> argenx's debt-to-equity ratio is below the industry average at <strong>0.0</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ARGX

Breaking Down argenx: 12 Analysts Share Their Views

OrganiGram Holdings (TSE:OGI) has released an update. OrganiGram Holdings Inc. is transitioning to a new auditor after KPMG LLP, the current audito...

OrganiGram Holdings Announces Auditor Change

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>As the cannabis market continues to expand globally, savvy investors are looking for top <a href="https://investorplace.com/industries/healthcare/cannabis/">cannabis stocks</a> to buy.</p>



<p>The global legal cannabis market is <a href="https://www.forbes.com/sites/irisdorbian/2024/03/07/global-legal-cannabis-market-expected-to-reach-58-billion-in-2028/?sh=2ed0cccd1d84">projected</a> to reach $58 billion by 2028, driven primarily by adult-use sales in the U.S., according to BDSA. Despite the dominance of the U.S. and Canada in the market, international sales of cannabis products are forecasted to grow significantly at a compounded annual growth rate (<span>CAGR</span>) of 24%.</p>



<p>This growth is also expected to be supported by governments, such as the Czech Republic&rsquo;s initiative to <a href="https://www.loc.gov/item/global-legal-monitor/2019-03-11/czech-republic-ministry-of-health-proposes-public-health-insurance-companies-reimburse-patients-for-medical-cannabis-costs/">subsidize</a> 90% of medical cannabis costs and the legalization of cannabis-based <a href="https://www.cannabisbusinesstimes.com/article/cannabis-legalization-world-map/">medicines</a> in more than 40 countries.</p>



<p>In light of these developments, here are three cannabis stocks that stand out as particularly promising buys for April 2024. Each of these companies has demonstrated strong business fundamentals, innovative product lines, and strategic market positioning, which could translate into significant investor returns in the coming years.</p>



<h2>Organigram (OGI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/01/marijuana-1600-300x169.png" alt="Marijuana leaves on various colors of green and yellow on top of a black background representing HITI stock."><div>Source: Hudozhnica_Ananas / Shutterstock</div></div><p><strong>Organigram</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ogi-stock-quote/"><strong>OGI</strong></a>) is one of the leading Canadian cannabis firms. The company has continued to grow at a high growth rate over the past few years. Organigram leverages strategic partnerships, such as its partnership with <strong>British American Tobacco</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/bti-stock-quote/"><strong>BTI</strong></a></span>). BAT&rsquo;s <a href="https://www.bat.com/media/press-releases/_2023/november/bat-to-strengthen-strategic-partnership-with-organigram">additional</a> investment in Organigram signifies a robust vote of confidence in the marijuana stock&rsquo;s operational capabilities and growth potential. The partnership aims to leverage Organigram&rsquo;s innovative prowess in developing new products, such as edibles and vape formulations.</p>



<p>During Q1 2024, the company <a href="https://seekingalpha.com/article/4669776-organigram-holdings-inc-ogi-q1-2024-earnings-call-transcript">generated</a> $26.8 million in revenue, with an adjusted EBITDA slightly above break-even. The company focused on geographic expansion during the quarter, and its international markets now include the U.K. and Germany. These markets offer higher price stability and margins compared to the Canadian recreational sector, presenting Organigram with lucrative growth opportunities.</p>



<p>Moreover, the <a href="https://twitter.com/Organigram_Inc/status/1735735765269663785">expansion</a> of its Lac-Sup&eacute;rieur facility is set to enhance Organigram&rsquo;s presence in the ultra-premium segment, promising higher margins and reinforcing its market position.</p>



<h2>Altria (MO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/10/cron1600a-300x169.jpg" alt="marijuana leaf in green traffic light"><div>Source: Shutterstock</div></div><p><strong>Altria</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/mo-stock-quote/"><strong>MO</strong></a>) has adeptly navigated the shifting landscape of tobacco and nicotine consumption by innovating and diversifying into less harmful alternatives such as vapes, e-cigarettes and nicotine pouches.</p>



<p>The tobacco giant has made significant strides in the cannabis market, particularly through its strategic <a href="https://www.sec.gov/Archives/edgar/data/764180/000119312519068180/d712964dex991.htm">investment</a> in <strong>Cronos Group</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/cron-stock-quote/"><strong>CRON</strong></a></span>). This investment, valued at $1.8 billion, granted Altria a substantial stake in Cronos and a foothold in the growing global cannabis market.</p>



<p>Altria&rsquo;s financial health remains robust, characterized by strong profitability and an impressive dividend yield of <a href="https://www.nasdaq.com/market-activity/stocks/mo/dividend-history">approximately</a> 9%. The company reported mixed results for Q4 2023. Altria reported an EPS of $1.18, which met expectations but its revenue of $5.02 billion missed estimates by $53.56 million.</p>



<p>Altria&rsquo;s stock is up 3.2% in 2024. Wall Street analysts are bullish on the company and have an <a href="https://finance.yahoo.com/quote/MO/">average&nbsp;</a>price target&nbsp;of $46.58 on the stock. That translates into an 8.52% potential upside in the near term.</p>



<h2>Curaleaf (CURLF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/cannabis-stocks1600-3-300x169.png" alt="scientist checking organic hemp wild plants in a cannabis weed commercial greenhouse. Concept of herbal alternative medicine, cbd oil, pharmaceutical industry. Cannabis stocks, FLGC stocks"><div>Source: Chokniti-Studio / Shutterstock.com</div></div><p><strong>Curaleaf</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/curlf-stock-quote/"><strong>CURLF</strong></a>) is a leading multi-state operator in the American cannabis industry. The company is recognized for its extensive network of dispensaries and broad product offerings.</p>



<p>Curaleaf has expanded its operations extensively, not just within the U.S. but across international markets as well, including Europe. The company&rsquo;s robust operational base <a href="https://www.prnewswire.com/news-releases/curaleaf-reports-fourth-quarter-and-full-year-ended-2023-results-302082061.html">includes</a> 145 dispensaries and more than 5,600 employees worldwide. This positions the company to benefit from the growth of the rising cannabis market. In particular, the adult-use cannabis markets in states like New York and Florida, where Curaleaf has established a significant presence, are expected to drive substantial revenue growth for the company.</p>



<p>The company achieved record revenue of $345 million in Q4 2023, up 4% sequentially, driven primarily by a 14% increase in wholesale sales. The company&rsquo;s stock price reflects Curaleaf&rsquo;s strong performance in recent times. The stock is up 30% year-to-date (YTD). However, Wall Street analysts remain bullish on the stock and have an average&nbsp;<a href="https://finance.yahoo.com/quote/CURLF/">price target</a>&nbsp;of $5.49 on the stock. That provides a near-term potential upside of 8.71%.</p>



<p><em>On the date of publication, Mohammed Saqib did not hold (either directly or indirectly) any positions in the securities mentioned in this article.</em>&nbsp;<em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em>Publishing Guidelines</em>.</a></p>
<div><p>Mohammed Saqib is a research analyst with experience in equity research and financial modeling. He has extensively covered stocks listed in the tech sector using fundamental analysis as the cornerstone of his approach. Currently pursuing a master&rsquo;s degree in finance, Saqib is dedicated to obtaining the CFA charter to augment his expertise in the field further.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/the-top-3-cannabis-stocks-to-buy-in-april-2024/">The Top 3 Cannabis Stocks to Buy in April 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The Top 3 Cannabis Stocks to Buy in April 2024

Why I Own No Village Farms In My Cannabis Model Portfolio

Constellation Brands has a 39% stake in Canopy but has announced that it has converted its stake in Canopy to a new category of shares which will result in an overall reduction in debt on the Canopy's balance sheet in the amount of C$100 million.

April Recap: Canadian Cannabis LP Portfolio Jumped 8%

Pot stocks surge on news of cannabis rescheduling

OMB review of cannabis rescheduling could put measure at risk

Cannabis stocks jumped 35%, on average, Tuesday with news that the DEA plans to follow a recommendation that would de-classification marijuana to a less stringently regulated Schedule III drug that can be prescribed with a prescription.

Déjà Vu: Cannabis Stocks Soared 35%, On Average, Tuesday - Here's Why

BTIG sees "murky" road ahead for cannabis reclassification

OrganiGram Holdings (TSE:OGI) has released an update. Organigram Holdings Inc., a prominent cannabis producer, is set to release its second quarter...

Organigram to Announce Q2 Fiscal 2024 Earnings

OrganiGram Holdings (TSE:OGI) has released an update. Organigram Holdings Inc., a major player in the cannabis industry, is set to release its seco...

Organigram to Unveil Q2 Fiscal 2024 Financials

AAWH

ACRHF

AYRWF

CNBS

CRLBF

CURLF

CWBHF

ETRGF

FLGC

GLASF

GRWG

HITI

JUSHF

LFLY

MAPS

MRMD

MSOS

PCLOF

PLNH

THCX

TSNDF

VRNOF

YCBD

YOLO

Press Releases

Organigram Reports First Quarter Fiscal 2024 Results

Organigram Applauds the Standing Committee on Finance's Recommendation on Excise Duty

Organigram Receives Health Canada's Final Redetermination on Jolts

Organigram Invests in U.S. Based Open Book Extracts Representing Inaugural Jupiter Investment

Organigram Announces Launch of Overnight Marketed Public Offering

Organigram Announces Pricing of Overnight Marketed Public Offering

Organigram Successfully Closes Previously Announced Underwritten Public Offering

Organigram's Popular SHRED Brand Surpasses $200 Million in Yearly Retail Sales

Organigram Recognized for Executive Gender Diversity by the Globe & Mail's Women Lead Here Report for the Fourth Consecutive Year

Organigram to Report Second Quarter Fiscal 2024 Results on May 14, 2024

TSX:OGI

Stifel

CIBC